All News
Interesting discussion about nocebo effect when swapping to biosimilars. “Cheaper” may trigger this.
Health professionals need to understand we are salespeople in many situations. Language, trust, style matter.
#EULAR2019 https://t.co/29GP6cmXhQ
Dr Irwin Lim _connectedcare ( View Tweet)
Optimal bimekizumab dose in PsA still remains to be determined.
Stefan Siebert StefanSiebert1 ( View Tweet)
Ritchlin: Bimekizumab (anti-IL17A & F) Phase 2B in active PsA = rapid response but also further increases wk12 to wk20 and sustained to wk48.
#eular2019 @RheumNow https://t.co/yblCNmTxR4
Stefan Siebert StefanSiebert1 ( View Tweet)
@_connectedcare @RheumNow Certainly good rationale for also blocking IL-17F from pathophysiology point of view but will need to see if leads to diffs in RCTs…may also be important for IBD/other conditions
Stefan Siebert StefanSiebert1 ( View Tweet)
@StefanSiebert1 @RheumNow Do you think (gut feel) the combined inhibition of A & F looks better than IL17A inhibition alone? I know hard to compare without H2H but given you’re in this field of research...#eular2019
Dr Irwin Lim _connectedcare ( View Tweet)
RELIEF clinical trial to evaluate efficacy a treatment for #Behçet's Syndrome.. #Apremilast 30 BID demonstrated efficacy at week 12 decreases activity in number and pain of oral ulcers.. - Gulen Hatemi #EULAR2019 https://t.co/iQHErUBIeO
Dr.Martínez MtzReuma ( View Tweet)
GIACTA follow-up #eular2019
RT @drdavidliew: Flares: well, I had hoped for more from that top highlighted line. What is going to happen to our real-life patients who have had a year of TCZ and then come off? https://t.co/iGQN5HjADd
Dr Irwin Lim _connectedcare ( View Tweet)
Motivating presentation on how to bring the future to the present, by Prof. McInnes.
Identifying clusters of patients with PsA using Machine Learning. First step to achieve a personalized treatment for every patient #EULAR2019 https://t.co/5xRECw0gG5
Diego Benavent Núñez DiegoBenavent ( View Tweet)
In a large Danish study of #RA patients, those on #biologics and those on conventional #DMARDs had the same incidence of #jointreplacement #EULAR2019 https://t.co/ZgdkVZ8sYa
CreakyJoints.org CreakyJoints ( View Tweet)
Ross Wilkie and his team found walking frequency, depression and insomnia are #mediators of #osteoarthritis effects on #mortality. https://t.co/sXhff6moFd
OACOP KeeleOACOP ( View Tweet)
What happens to the #muscles in patients with Giant Cell Arteritis after prolonged #steroid treatment?🤔
Find out at #EULAR2019 poster THU0605
Dr Alfuraih will explain using #ultrasound #shearwave #elastography
#muscle #imaging https://t.co/VrzfdNiE3I
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
#Lupus associated genetic variants contribute to organ damage #EULAR2019 https://t.co/644BudBQyp
Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
Thomas Dorner tells us not to lose hope in lupus trials, and that they are just following what is called the Kuhn cycle! https://t.co/xeaaUwfwgp #EULAR2019
Alberta Hoi tuna0sashimi ( View Tweet)
Genentech presenta nuevos datos sobre un nuevo tratamiento para el Lupus con afectación renal. Obinituzumab, Nueva esperanza para pacientes con nefritis lúpica! #EULAR2019 https://t.co/Jjl5zTBKGN
Jose María Alvaro Gracia AlvaroGraciaSER ( View Tweet)
Dr Ross Wilkie won one of the Best Abstract Awards at the European Congress of Rheumatology #EULAR2019. His study identified targets for reducing premature death in older people with #osteoarthritis. Great research led by health professionals. #HPR https://t.co/RZ2salIn3M https://t.co/huAilBKUCG
Links:
Mwidimi Ndosi ndosie ( View Tweet)
Co-founder and Director of dotMD Dr Ronan Kavanagh explains what was involved in choosing speakers for this year’s conference https://t.co/FFiqxje4HF @DotMDConf @RonanTKavanagh
Links:
Medical Independent med_indonews ( View Tweet)
Minimal Disease Activity in PsA is more challenging in women than in men. Unpublished data from the TICOPA trial presented by Dr. Laura Coates. #PsA #EULAR2019
Xabier Michelena Vegas xabiermich ( View Tweet)
What factors are linked with fatigue in women in the first year of #RA? One #EULAR2019 study found these 4: obesity, steroid use, seronegativity, and poor sleep https://t.co/40lyEXjE2U
CreakyJoints.org CreakyJoints ( View Tweet)
New anti-CD20 Mab Obinutuzumab just delivered positive results in its phase 2 study in lupus nephritis. We need to know more! #EULAR2019 https://t.co/Bx9OdmEtpy
Alberta Hoi tuna0sashimi ( View Tweet)
Hydroxychloroquine: proposed risk factors for Retinopathy #EULAR2019 https://t.co/WkyNZ4GPVr
Dr Irwin Lim _connectedcare ( View Tweet)